Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Myelodysplastic Syndrome in Adolescent and Young Adult Patients

ConclusionIn the present study, the epidemiology of AYA patients with MDS who received allogeneic HSCT for the first time, and the prognostic factors influencing 5yOS were evaluated. Our results provide physicians with additional information for the treatment of AYA patients with MDS.DisclosuresMori: Novartis Pharma: Research Funding; Astella Pharma: Honoraria; Shire Japan: Honoraria; Taisho Toyama Pharmaceutical Co: Honoraria; Japan Blood Products Organization: Honoraria; Eisai: Honoraria; Janssen: Honoraria; MSD: Research Funding; SHIONOGI: Honoraria; Pfizer: Honoraria; CHUGAI: Honoraria; Novartis Pharma: Honoraria; MSD: Honoraria; Ono: Honoraria; Celgene: Honoraria; Asahi Kasei: Research Funding; Kyowa Hakko Kirin: Honoraria. Tanaka: Bristol-Myers Squibb: Honoraria, Research Funding; Otsuka: Honoraria; Novartis Pharma: Honoraria; Pfizer: Honoraria. Ishiyama: Alexion Pharmaceuticals, Inc.: Honoraria.

Source: Blood - November 21, 2018 Category: Hematology Authors: Shimomura, Y., Hara, M., Konuma, T., Itonaga, H., Ohashi, K., Ozawa, Y., Eto, T., Uchida, N., Mori, T., Tanaka, J., Fukuda, T., Atsuta, Y., Ishikawa, T., Ishiyama, K. Tags: 732. Clinical Allogeneic Transplantation: Results: Poster II Source Type: research